New Insights into the Nephroprotective Potential of Lercanidipine.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Hypertension* ; Dihydropyridines*/pharmacology ; Dihydropyridines*/therapeutic use ; Renal Insufficiency, Chronic*/drug therapy ; Renal Insufficiency, Chronic*/complications; Humans ; Calcium Channel Blockers/pharmacology ; Calcium Channel Blockers/therapeutic use ; Antihypertensive Agents/pharmacology ; Antihypertensive Agents/therapeutic use ; Blood Pressure

Kidneys are responsible for many crucial biological processes in the human body, including maintaining the water-electrolyte balance, pH, and blood pressure (BP), along with the elimination of toxins. Despite this, chronic kidney disease (CKD), which affects more and more people, is a disease that develops insidiously without causing any symptoms at first. The main purpose of this article is to summarize the existing literature on lercanidipine, with a particular focus on its nephroprotective properties. Lercanidipine is a third-generation dihydropyridine (DHP) blocker of calcium channels, and as such it possesses unique qualities such as high lipophilicity and high vascular selectivity. Furthermore, it acts by reversibly inhibiting L-type and T-type calcium channels responsible for exerting positive renal effects. It has been shown to reduce tissue inflammation and tubulointerstitial fibrosis, contributing to a decrease in proteinuria. Moreover, it exhibited antioxidative effects and increased expression of molecules responsible for repairing damaged tissues. It also decreased cell proliferation, preventing thickening of the vascular lumen. This article summarizes studies simultaneously comparing the effect of lercanidipine with other antihypertensive drugs. There is still a lack of studies on the medications used in patients with CKD, and an even greater lack of studies on those used in patients with concomitant hypertension. Therefore, further studies on lercanidipine and its potential in hypertensive patients with coexisting CKD are required.

Int Angiol. 2013 Feb;32(1):85-93. (PMID: 23435396)
Front Med (Lausanne). 2022 May 04;9:822870. (PMID: 35602498)
Clin Pharmacokinet. 1998 Nov;35(5):361-90. (PMID: 9839089)
Curr Med Res Opin. 2015 Jan;31(1):163-70. (PMID: 25425058)
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):343-6. (PMID: 15556551)
Pharmacol Res. 2009 Jan;59(1):48-56. (PMID: 18973813)
Curr Med Res Opin. 2016 Oct;32(sup2):35-41. (PMID: 27779461)
Circulation. 2003 Dec 16;108(24):3042-7. (PMID: 14638548)
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13527-32. (PMID: 12370443)
Br J Pharmacol. 2004 May;142(2):275-84. (PMID: 15155536)
J Cardiovasc Pharmacol Ther. 2007 Jun;12(2):145-52. (PMID: 17562785)
Int Angiol. 2001 Jun;20(2):136-40. (PMID: 11533521)
Adv Ther. 2008 Apr;25(4):300-20. (PMID: 18449492)
Oxid Med Cell Longev. 2015;2015:854015. (PMID: 26180597)
High Blood Press Cardiovasc Prev. 2020 Feb;27(1):43-49. (PMID: 31916208)
Drugs. 1999 May;57(5):665-93. (PMID: 10353294)
Drugs Today (Barc). 2008 Apr;44(4):261-70. (PMID: 18536784)
Vasc Health Risk Manag. 2008;4(6):1159-66. (PMID: 19337529)
Curr Hypertens Rev. 2013 Aug;9(3):182-6. (PMID: 24479750)
J Cardiovasc Pharmacol. 2004 Oct;44(4):416-22. (PMID: 15454849)
Expert Opin Pharmacother. 2007 Oct;8(14):2215-23. (PMID: 17927478)
J Clin Hypertens (Greenwich). 2003 Jul-Aug;5(4):249-53. (PMID: 12939564)
Nephrology (Carlton). 2021 May;26(5):377-390. (PMID: 33283420)
J Pharmacol Pharmacother. 2017 Oct-Dec;8(4):155-165. (PMID: 29472747)
Diabetes. 2004 Aug;53(8):2101-9. (PMID: 15277392)
Pharmacol Ther. 2013 Apr;138(1):103-41. (PMID: 23333322)
J Hypertens Suppl. 1998 Sep;16(4):S17-25. (PMID: 9817188)
Circ Res. 2001 Sep 28;89(7):630-8. (PMID: 11577029)
Am J Nephrol. 2003 Jul-Aug;23(4):229-44. (PMID: 12840599)
Cardiovasc Ther. 2008 Spring;26(1):2-9. (PMID: 18466416)
Am J Nephrol. 2022;53(10):730-739. (PMID: 36481730)
Jpn J Pharmacol. 1999 Jul;80(3):199-208. (PMID: 10461764)
Blood Press. 2002;11(2):95-100. (PMID: 12035878)
Int J Clin Pract. 2008 May;62(5):723-8. (PMID: 18355238)
Biomedicines. 2023 Aug 09;11(8):. (PMID: 37626732)
EMBO J. 2003 Nov 17;22(22):6027-34. (PMID: 14609949)
Hypertension. 1999 Oct;34(4 Pt 1):673-8. (PMID: 10523345)
Clin Ther. 2009 Aug;31(8):1652-63. (PMID: 19808126)
Clin Ther. 2015 Aug;37(8):1726-39. (PMID: 26164786)
Vasc Health Risk Manag. 2005;1(3):173-82. (PMID: 17319103)
Endokrynol Pol. 2021;72(6):589-591. (PMID: 34970990)
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):4025-4031. (PMID: 29949180)
Future Cardiol. 2019 Jul;15(4):259-266. (PMID: 31180724)
Cell Metab. 2021 Apr 6;33(4):732-739. (PMID: 33691091)
Ren Fail. 2008;30(3):247-55. (PMID: 18350443)
J Am Board Fam Med. 2013 Sep-Oct;26(5):529-38. (PMID: 24004705)
Vasc Health Risk Manag. 2016 Nov 15;12:443-451. (PMID: 27895487)
J Cardiovasc Pharmacol. 2002 Jan;39(1):39-48. (PMID: 11743226)
J Clin Pharmacol. 2020 Jan;60(1):75-85. (PMID: 31353479)
Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. (PMID: 11996015)
Drugs. 2000 Nov;60(5):1123-40. (PMID: 11129125)
Br J Pharmacol. 1998 Dec;125(7):1471-6. (PMID: 9884075)
Arzneimittelforschung. 1996 Feb;46(2):145-52. (PMID: 8720303)
Hypertension. 2003 Mar;41(3):558-62. (PMID: 12623959)
Drugs. 2003;63(22):2449-72. (PMID: 14609358)
Am J Ther. 2002 Sep-Oct;9(5):444-53. (PMID: 12237738)
FASEB J. 2006 May;20(7):994-6. (PMID: 16597674)
Clin Pharmacol Ther. 2002 Sep;72(3):302-7. (PMID: 12235451)
Colloids Surf B Biointerfaces. 2011 Sep 1;86(2):327-38. (PMID: 21550214)
Circ Res. 2015 Mar 13;116(6):976-90. (PMID: 25767284)
Proc Natl Acad Sci U S A. 1992 May 1;89(9):4071-5. (PMID: 1570335)
Keio J Med. 2010;59(3):84-95. (PMID: 20881449)
Am J Kidney Dis. 2001 Dec;38(6):1292-7. (PMID: 11728963)
Am J Hypertens. 2003 Jul;16(7):596-9. (PMID: 12850395)
Kardiol Pol. 2005 Oct;63(4 Suppl 2):S457-61. (PMID: 20527401)
Nephron. 2000 May;85(1):71-80. (PMID: 10773759)
Curr Med Chem. 2021;28(20):3925-3934. (PMID: 33023428)
Immunopharmacology. 2000 May;47(2-3):119-25. (PMID: 10878286)
Lancet Neurol. 2010 May;9(5):469-80. (PMID: 20227347)
Ren Fail. 2005;27(1):73-80. (PMID: 15717638)
Nephrol Dial Transplant. 1997 Nov;12(11):2244-50. (PMID: 9394306)
Kidney Int. 2022 Nov;102(5S):S1-S127. (PMID: 36272764)
J Hypertens. 1998 Dec;16(12 Pt 1):1831-8. (PMID: 9869018)
Int J Clin Pract. 2006 Nov;60(11):1364-70. (PMID: 17073834)
J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. (PMID: 16424795)
Pediatr Clin North Am. 2019 Feb;66(1):247-267. (PMID: 30454747)
Vascul Pharmacol. 2017 May;92:16-21. (PMID: 26070528)
Am J Hypertens. 2002 Nov;15(11):932-40. (PMID: 12441211)
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. (PMID: 19619074)
Arzneimittelforschung. 2002;52(3):155-61. (PMID: 11963641)
Cells. 2022 Mar 10;11(6):. (PMID: 35326393)
Am J Med. 1985 Sep 27;79(3C):24-30. (PMID: 4050826)
Eur Rev Med Pharmacol Sci. 2022 Oct;26(20):7482-7492. (PMID: 36314318)
Ther Clin Risk Manag. 2014;10:17-26. (PMID: 24379677)
J Clin Invest. 2004 May;113(10):1430-9. (PMID: 15146240)
FASEB J. 1997 Feb;11(2):118-24. (PMID: 9039953)
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H415-25. (PMID: 16980345)
Curr Hypertens Rev. 2013 Aug;9(3):210-8. (PMID: 24479751)
Am J Nephrol. 2002 Sep-Dec;22(5-6):581-6. (PMID: 12381964)
Curr Opin Allergy Clin Immunol. 2004 Aug;4(4):267-70. (PMID: 15238791)
Kidney Int. 1988 May;33(5):917-24. (PMID: 3292816)
Expert Opin Investig Drugs. 1999 Jul;8(7):1043-62. (PMID: 15992105)
Kidney Int. 2019 Aug;96(2):283-286. (PMID: 31331468)
BMJ Open. 2018 Jul 11;8(7):e020192. (PMID: 29997136)
J Hypertens. 2018 Dec;36(12):2284-2309. (PMID: 30379783)
J Hypertens. 1996 Nov;14(11):1259-63. (PMID: 8934351)
Kidney Int. 2004 Jun;65(6):1991-2002. (PMID: 15149313)
Heart Vessels. 2009 Jul;24(4):301-7. (PMID: 19626404)
J Clin Pharm Ther. 2014 Jun;39(3):277-85. (PMID: 24635387)
Nutrients. 2021 Sep 19;13(9):. (PMID: 34579153)
Int J Biol Macromol. 2015 Jan;72:218-22. (PMID: 25159878)
Rev Med Suisse. 2006 Sep 13;2(78):2047-50, 2052-3. (PMID: 17019840)
Hypertens Res. 2017 Jan;40(1):21-28. (PMID: 27412800)
Hypertension. 2000 Mar;35(3):775-9. (PMID: 10720594)
Curr Mol Pharmacol. 2015;8(2):110-22. (PMID: 25966690)
J Hypertens. 1999 Dec;17(12 Pt 2):1837-41. (PMID: 10703877)
J Hypertens. 2016 Jan;34(1):139-48. (PMID: 26630216)
J Am Soc Nephrol. 1990 Sep;1(3 Suppl 1):S13-20. (PMID: 16989073)
J Cardiovasc Pharmacol. 1996 Nov;28(5):687-94. (PMID: 8945683)
J Hum Hypertens. 2002 Aug;16(8):605-10. (PMID: 12149668)
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. (PMID: 31939529)
Br J Clin Pharmacol. 2003 Jul;56(1):120-4. (PMID: 12848784)
Stroke. 2011 Oct;42(10):2860-5. (PMID: 21817143)
Curr Med Res Opin. 2013 Dec;29(12):1727-35. (PMID: 24069902)
Hypertension. 2003 Apr;41(4):950-5. (PMID: 12642509)
Blood Press Suppl. 1998;2:10-7. (PMID: 9850437)
Kidney Int. 1996 Mar;49(3):868-79. (PMID: 8648932)
Clin Ther. 2007 Apr;29(4):563-80. (PMID: 17617280)
Arch Gerontol Geriatr. 2003 Nov-Dec;37(3):203-12. (PMID: 14511846)
J Hypertens. 2011 Jul;29(7):1270-80. (PMID: 21558959)
Patient Prefer Adherence. 2012;6:449-55. (PMID: 22791982)
Prim Care. 2020 Dec;47(4):585-595. (PMID: 33121630)
Fundam Clin Pharmacol. 2004 Jun;18(3):309-19. (PMID: 15147282)
Pharmacol Rep. 2020 Apr;72(2):350-359. (PMID: 32124390)
Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316-28. (PMID: 16054557)
J Hypertens. 2014 Aug;32(8):1700-7; discussion 1707. (PMID: 24906174)
Clin Chim Acta. 2019 Dec;499:54-63. (PMID: 31476302)
Circulation. 1999 May 18;99(19):2523-9. (PMID: 10330383)
Curr Med Res Opin. 2016 Oct;32(sup2):29-34. (PMID: 27779460)
Clin Exp Hypertens. 2012;34(2):113-7. (PMID: 21967031)
Eur J Pharm Biopharm. 2016 Jun;103:179-191. (PMID: 27063592)
Am J Kidney Dis. 2019 Jul;74(1):120-131. (PMID: 30898362)
Hypertension. 1990 Feb;15(2 Suppl):I76-80. (PMID: 1688825)
Clin Pharmacokinet. 2000 Jan;38(1):41-57. (PMID: 10668858)
J Pharmacol Exp Ther. 2000 Sep;294(3):948-54. (PMID: 10945845)
Aging (Milano). 2000 Oct;12(5):375-9. (PMID: 11126524)
Curr Med Res Opin. 2015 Jan;31(1):183-6. (PMID: 25424689)
Psychiatr Pol. 2019 Oct 30;53(5):977-995. (PMID: 31955180)
Transplantation. 1999 Jun 15;67(11):1411-7. (PMID: 10385078)
Eur J Pharmacol. 2008 Dec 3;599(1-3):110-6. (PMID: 18930722)
J Hum Hypertens. 2007 Dec;21(12):917-24. (PMID: 17581601)
J Bras Nefrol. 2019 Jan-Mar;41(1):124-130. (PMID: 30281062)
J Cardiovasc Pharmacol. 2002 Jul;40(1):133-9. (PMID: 12072586)
Arzneimittelforschung. 1996 Jan;46(1):15-24. (PMID: 8821512)
Curr Med Res Opin. 2017 Jun;33(6):1111-1117. (PMID: 28300435)
Eur J Hosp Pharm. 2023 May 26;:. (PMID: 37236776)

Keywords: calcium channel blockers; chronic kidney disease; dihydropyridines; lercanidipine; renal protection

0 (Calcium Channel Blockers)
V7XTJ4R0BH (lercanidipine)
0 (Antihypertensive Agents)
0 (Dihydropyridines)

Date Created: 20230928 Date Completed: 20231004 Latest Revision: 20231004

20240829

PMC10531189

10.3390/ijms241814048

37762350